Related Experiment Videos
Management of multiple myeloma
1Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock 72205.
Abstract:
There has been little progress in the treatment of patients with multiple myeloma, and the average survival time is still only about 3 years. Although there have been significant therapeutic advances in recent years, clinical trials have only just begun. The major concern is, of course, the achievement of major disease control (which can be equated with a cure). The data available to date indicate that this is possible only with the use of allogeneic bone marrow transplantation, with which a survival plateau of around 30% can be attained. The trials should perhaps include the sequential use of all regimens with established efficacy in refractory myeloma. Immunoconjugate therapy with either radioisotopes or cytotoxic agents could also be envisioned, and expansion with suitable biological agents such as interleukin-2 could be considered. There is a plethora of promising treatment possibilities and novel concepts that may improve the dismal outlook for patients with multiple myeloma.
Insights
Multiple myeloma treatment shows limited progress, with a 3-year survival rate. Allogeneic bone marrow transplantation offers a potential cure, achieving a 30% survival plateau in clinical trials.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Background:
- Multiple myeloma has a poor prognosis with limited treatment advancements.
- Current average survival for multiple myeloma patients is approximately 3 years.
Purpose of the Study:
- To review current therapeutic strategies for multiple myeloma.
- To explore novel treatment possibilities and concepts for improving patient outcomes.
Main Methods:
- Review of existing clinical trial data and therapeutic regimens.
- Discussion of potential future treatment modalities including transplantation and immunotherapy.
Main Results:
- Allogeneic bone marrow transplantation demonstrates potential for disease control, achieving a 30% survival plateau.
- Sequential use of established regimens and novel agents like interleukin-2 show promise.
Conclusions:
- Significant therapeutic advances are emerging, but clinical trials are in early stages.
- Novel concepts and immunoconjugate therapy offer hope for improving the outlook for multiple myeloma patients.